Literature DB >> 34686394

Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United States.

Emmanuelle A Dankwa1, Christl A Donnelly2, Andrew F Brouwer3, Rui Zhao4, Martha P Montgomery5, Mark K Weng5, Natasha K Martin6.   

Abstract

BACKGROUND: Between September 2017 and June 2019, an outbreak of hepatitis A virus (HAV) occurred in Louisville, Kentucky, resulting in 501 cases and 6 deaths, predominantly among persons who experience homelessness or who use drugs (PEH/PWUD). The critical vaccination threshold (Vc) required to achieve herd immunity in this population is unknown. We investigated Vc and vaccination impact using epidemic modeling.
METHODS: To determine which population subgroups had high infection risks, we employed a technique based on comparing the proportion of cases arising before and after the epidemic peak, across subgroups. We also developed a dynamic deterministic model of HAV transmission among PEH/PWUD to estimate the basic reproduction number (R0), herd immunity threshold, Vc and the effect of timing of the vaccination intervention on epidemic and economic outcomes.
RESULTS: Of the 501 confirmed or probable cases, 385 (76.8%) were among PEH/PWUD. Among PEH/PWUD and within the general population, homelessness was a significant risk factor for infection in the initial stages of the outbreak (odds ratios for homeless versus not homeless: 2.62; 95% confidence interval (CI): 1.62-4.25 for PEH/PWUD and 2.39; 95% CI: 1.51-3.78 for all detected cases). Our estimate for R0 ranges between 2.85 and 3.54, corresponding to an estimate of 69% (95% CI: 65-72) for herd immunity threshold and 76% (95% CI: 72%-80%) for Vc, assuming a vaccine with 90% efficacy. The observed vaccination program was estimated to have averted 30 hospitalizations (95% CI: 19-43), associated with over US$490 000 (95% CI: $310 000-700 000) in hospitalization cost. Greater impact was observed with earlier and faster vaccination implementation.
CONCLUSIONS: Vaccination coverage of at least 77% is likely required to prevent outbreaks of HAV among PEH/PWUD in Louisville, assuming a 90% vaccine efficacy. Proactive hepatitis A vaccination programs among PEH/PWUD will maximize health and economic benefits of these programs and reduce the likelihood of another outbreak.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Critical vaccination coverage; Dynamic modeling; Hepatitis A; Herd immunity; Persons who experience homelessness or who use drugs

Mesh:

Substances:

Year:  2021        PMID: 34686394      PMCID: PMC9128446          DOI: 10.1016/j.vaccine.2021.10.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   4.169


  31 in total

Review 1.  The health of homeless people in high-income countries: descriptive epidemiology, health consequences, and clinical and policy recommendations.

Authors:  Seena Fazel; John R Geddes; Margot Kushel
Journal:  Lancet       Date:  2014-10-25       Impact factor: 79.321

Review 2.  Perspectives on the basic reproductive ratio.

Authors:  J M Heffernan; R J Smith; L M Wahl
Journal:  J R Soc Interface       Date:  2005-09-22       Impact factor: 4.118

Review 3.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

4.  A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization.

Authors:  Thierry P Van Effelterre; Thomas K Zink; Bernard J Hoet; William P Hausdorff; Philip Rosenthal
Journal:  Clin Infect Dis       Date:  2006-06-12       Impact factor: 9.079

Review 5.  The effectiveness and safety of hepatitis A vaccine: a systematic review.

Authors:  Vittorio Demicheli; Donatella Tiberti
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

6.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

7.  Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018.

Authors:  Peng-Jun Lu; Mei-Chuan Hung; Anup Srivastav; Lisa A Grohskopf; Miwako Kobayashi; Aaron M Harris; Kathleen L Dooling; Lauri E Markowitz; Alfonso Rodriguez-Lainz; Walter W Williams
Journal:  MMWR Surveill Summ       Date:  2021-05-14

8.  Bayesian modelling of a hepatitis A outbreak in men who have sex with men in Sydney, Australia, 1991/1992.

Authors:  X-S Zhang; A Charlett
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

9.  Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness - California, Kentucky, Michigan, and Utah, 2017.

Authors:  Monique Foster; Sumathi Ramachandran; Katie Myatt; Danielle Donovan; Susan Bohm; Jay Fiedler; Bree Barbeau; Jim Collins; Douglas Thoroughman; Eric McDonald; Jonathan Ballard; Jeffrey Eason; Cynthia Jorgensen
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-11-02       Impact factor: 17.586

View more
  2 in total

1.  Detection and control of an ongoing international outbreak of hepatitis A among the Irish Traveller community beginning September 2020.

Authors:  David Kelly; Colette O'Hare; Paul McKeown; Fiona Cianci; Sarah Doyle
Journal:  Epidemiol Infect       Date:  2022-02-16       Impact factor: 2.451

2.  Transmission dynamics of the 2016-18 outbreak of hepatitis A among men who have sex with men in England and cost-effectiveness analysis of vaccination strategies to prevent future outbreaks.

Authors:  Xu-Sheng Zhang; Jason J Ong; Louis Macgregor; Tatiana G Vilaplana; Simone T Heathcock; Miranda Mindlin; Peter Weatherburn; Ford Hickson; Michael Edelstein; Sema Mandal; Peter Vickerman
Journal:  Lancet Reg Health Eur       Date:  2022-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.